Janux Therapeutics Inc share price logo

Janux Therapeutics Inc

NASDAQ: JANX

Small Cap

$16.50

-0.96

(-5.52%)

as on

Janux Therapeutics Inc Stock Performance

as on September 24, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $16.34
    $17.47
    downward going graph

    0.97%

    Downside

    5.88%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $12.12
    $35.34
    downward going graph

    26.55%

    Downside

    114.18%

    Upside

    downward going graph

Janux Therapeutics Inc share price movements today

Previous Close
$17.47
Open
$17.21
Volume
937.4K
Market Cap
$1.1B
Day's Low - High
$16.34 - $17.47
52 Week Low - High
$12.12 - $35.34

Janux Therapeutics Inc Historical Returns

1 Month Return
-11.18 %
3 Month Return
+ 12.84 %
1 Year Return
-27.67 %
3 Year Return
+ 72.08 %
5 Year Return
-20.19 %

Janux Therapeutics Inc Stock Fundamentals & Key Indicators

Check Janux Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.1B

EPS (TTM)

-1.64

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-10.65

Industry PE ratio

-6.66

PEG Ratio

-1.4975322596412408

EBITDA

-101.1M

Revenue (TTM)

31.9M

Profit Margin

68.91%

Return On Equity TTM

-10.79%

Janux Therapeutics Inc Stock Valuation

Track how Janux Therapeutics Inc P/E has moved over time to understand its valuation trends.

Janux Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (-41.83x)

December 31, 2024

Today (-7.54x)

December 31, 2025

Industry (-6.66x)

December 31, 2025

Highest (-7.54x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -7.54x

Janux Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Janux Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$1.1B-20.19%-10.6568.91%0.00%
Neutral$72.9B-57.66%-22.88-12.57%0.00%
StrongBuy$-180.48%29.7386.04%0.00%
Buy$82.2B25.5%19.284.86%0.46%

Stock Returns calculator for Janux Therapeutics Inc Stock including INR - Dollar returns

The Janux Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Janux Therapeutics Inc investment value today

Current value as on today

₹77,881

Returns

-₹22,119

(-22.12%)

Returns from Janux Therapeutics Inc Stock

-₹27,758 (-27.76%)

Dollar Impact

₹5,639 (+5.64%)

Analyst Recommendation on Janux Therapeutics Inc Stock

Based on 9 analysts

BUY

88.89%

Buy

0.00%

Hold

11.11%

Sell

Based on 9 analysts, 88.88888888888889% of analysts recommend a 'BUY' rating for Janux Therapeutics Inc. Average target price of $36.24

Janux Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Janux Therapeutics Inc.

What analysts predicted

54.47%UPSIDE

Target Price

$36.24

Current Price

$16.5

Analyzed by

9 Analysts

Target

$36.24

Janux Therapeutics Inc target price $36.24, a slight upside of 54.47% compared to current price of $16.5. According to 9 analysts rating.

Indian Investors' Interest in Janux Therapeutics Inc Stock

Search interest for Janux Therapeutics Inc Stock has increased by 14% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:14% versus previous 30 day period

Janux Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
1
8
0
-
-
-
10
7
3
10
Gross Profit
0
8
-1
-20
-25
-29
9
-1
3
10
Operating Income
-20
-13
-35
-29
-34
-45
-35
-42
-34
-31
EBITDA
-14
-5
-27
-19
-22
-33
-23
-31
-23
-21
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-14
-5
-28
-20
-23
-33
-24
-31
-24
-21
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-14
-5
-28
-20
-23
-33
-24
-31
-24
-21
Net Profit Margin
57.51%
94.31%
100.00%
0.00%
0.00%
0.00%
94.99%
-13.45%
87.44%
100.00%

Janux Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
3
8
8
10
10
Gross Profit
0
0
-22
7
6
8
7
Operating Income
-3
-4
-32
-67
-72
-98
-157
EBITDA
-3
-6
-32
-62
-56
-66
-111
Interest Expense
0
0
-
-
-
-
-
Depreciation
0
0
0
0
1
2
2
Income Before Tax
-4
-6
-32
-63
-58
-68
-113
Income Tax Expense
-
-
-
-
-
-
-
Net Income
-4
-6
-32
-63
-58
-68
-113
Net Profit Margin
0.00%
0.00%
100.00%
90.23%
75.81%
80.54%
79.71%

Janux Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-14
-5
-28
-20
-23
-33
-24
-31
-24
-46
Operating Cash Flow
-14
-10
-2
-16
-17
-23
-12
-28
-12
0
Investing Cash Flow
-113
-190
12
33
-340
1
8
29
8
-30
Financing Cash Flow
322
2
1
386
0
0
0
2
3
5
Change in Cash
193
-198
12
403
-356
-21
-4
3
0
-24

Janux Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-4
-6
-32
-63
-58
-68
-113
Operating Cash Flow
-3
-4
-16
-42
-50
-43
-82
Investing Cash Flow
-
-
-340
58
-41
-258
-300
Financing Cash Flow
4
11
386
0
59
713
4
Change in Cash
0
7
28
15
-32
411
-378

Mutual Funds that own Janux Therapeutics Inc Stock

Check out the Mutual Funds with significant holdings in Janux Therapeutics Inc.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
2.891274%
1767632
Fidelity Concord Street Trust
1.431838%
875380
JANUS INVESTMENT FUND
1.177808%
720074
VANGUARD HORIZON FUNDS
0.886762%
542138
Fidelity Salem Street Trust
0.781469%
477765

Global Institutional Holdings in Janux Therapeutics Inc

Funds
Holdings
Peter Kolchinsky
18.3%
iShares
4.13%
Vanguard
3.69%
SPDR
3.53%
VANGUARD INDEX FUNDS
2.89%

Janux Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 02 December

    Tue, 10:03 PM

    -

    Janux Therapeutics stock fell 47% after disappointing early-stage prostate cancer trial data.

Insights on Janux Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -31.94M → -21.97M (in $), with an average increase of 21.0% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 3.73M → 10.26M (in $), with an average increase of 63.6% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, JANX stock has moved up by 3.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 82.6% return, outperforming this stock by 0.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 605.4% return, outperforming this stock by 628.9%

About Janux Therapeutics Inc

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
OrganisationJanux Therapeutics Inc
Headquarters10955 Vista Sorrento Parkway, San Diego, CA, 92130, US
IndustryBiotechnology
CEODavid Alan Campbell
E-voting on sharesClick here to vote

Key Management of Janux Therapeutics Inc

Name

Title

Ms. Mandie Forman-Sklansky

Head of Human Resources

Dr. David Alan Campbell Ph.D.

President, Co-Founder, CEO & Director

Dr. Thomas Diraimondo Ph.D.

Chief Scientific Officer

Ms. Janeen Doyle

Chief Corporate & Business Development Officer

Mr. Matt Whitmire

Vice President of Finance

Ms. Maria Dobek

Vice President of Accounting

Mr. Charles M. Winter

Chief Technical Officer

Mr. James Pennington

General Counsel & Corporate Secretary

FAQs

What is Janux Therapeutics Inc share price today?

Janux Therapeutics Inc share price today is $16.50 as on at the close of the market. Janux Therapeutics Inc share today touched a day high of $17.47 and a low of $16.34.

What is the 52 week high and 52 week low for Janux Therapeutics Inc share?

Janux Therapeutics Inc share touched a 52 week high of $35.34 on and a 52 week low of $12.12 on . Janux Therapeutics Inc stock price today i.e. is closed at $16.50,which is 53.31% down from its 52 week high and 36.14% up from its 52 week low.

What is Janux Therapeutics Inc's market capitalisation today?

Janux Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Janux Therapeutics Inc Stock (JANX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Janux Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Janux Therapeutics Inc Shares that will get you 0.0909 shares as per Janux Therapeutics Inc share price of $16.50 per share as on September 24, 2026 at 1:29 am IST.

What is the minimum amount required to buy Janux Therapeutics Inc Stock (JANX) from India?

Indian investors can start investing in Janux Therapeutics Inc (JANX) shares with as little as ₹95.74 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.40 in Janux Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Janux Therapeutics Inc share’s latest price of $16.50 as on September 24, 2026 at 1:29 am IST, you will get 0.6061 shares of Janux Therapeutics Inc. Learn more about fractional shares .

What are the returns that Janux Therapeutics Inc has given to Indian investors in the last 5 years?

Janux Therapeutics Inc stock has given -20.19% share price returns and 29.82% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?